PDF DatasheetHuman Anti-p63 Antibody Product Attributes
p63 Previously Observed Antibody Staining Patterns
Observed Subcellular, Organelle Specific Staining Data:
Anti-TP63 antibody staining is expected to be primarily localized to the nucleoplasm.
Observed Antibody Staining Data By Tissue Type:
Variations in p63 antibody staining intensity in immunohistochemistry on tissue sections are present across different anatomical locations. An intense signal was observed in myoepithelial cells in the breast, respiratory epithelial cells in the bronchus, squamous epithelial cells in the cervix, uterine, glandular cells in the epididymis, squamous epithelial cells in the esophagus, respiratory epithelial cells in the nasopharynx, squamous epithelial cells in the oral mucosa, keratinocytes in skin, Langerhans in skin, melanocytes in skin, epidermal cells in the skin, squamous epithelial cells in the tonsil, urothelial cells in the urinary bladder and squamous epithelial cells in the vagina. More moderate antibody staining intensity was present in myoepithelial cells in the breast, respiratory epithelial cells in the bronchus, squamous epithelial cells in the cervix, uterine, glandular cells in the epididymis, squamous epithelial cells in the esophagus, respiratory epithelial cells in the nasopharynx, squamous epithelial cells in the oral mucosa, keratinocytes in skin, Langerhans in skin, melanocytes in skin, epidermal cells in the skin, squamous epithelial cells in the tonsil, urothelial cells in the urinary bladder and squamous epithelial cells in the vagina. Low, but measureable presence of p63 could be seen inglandular cells in the breast, cervix, uterine. We were unable to detect p63 in other tissues. Disease states, inflammation, and other physiological changes can have a substantial impact on antibody staining patterns. These measurements were all taken in tissues deemed normal or from patients without known disease.
Observed Antibody Staining Data By Tissue Disease Status:
Tissues from cancer patients, for instance, have their own distinct pattern of p63 expression as measured by anti-p63 antibody immunohistochemical staining. The average level of expression by tumor is summarized in the table below. The variability row represents patient to patient variability in IHC staining.
| Sample Type | breast cancer | carcinoid | cervical cancer | colorectal cancer | endometrial cancer | glioma | head and neck cancer | liver cancer | lung cancer | lymphoma | melanoma | ovarian cancer | pancreatic cancer | prostate cancer | renal cancer | skin cancer | stomach cancer | testicular cancer | thyroid cancer | urothelial cancer |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Signal Intensity | + | – | ++ | – | – | – | +++ | – | ++ | – | – | + | – | – | – | +++ | – | + | – | +++ |
| TP63 Variability | + | ++ | ++ | ++ | ++ | + | + | ++ | ++ | + | ++ | ++ | + | + | + | + | + | ++ | ++ | + |
| p63 General Information | |
|---|---|
| Alternate Names | |
| Tumor protein p63 transformation-related protein 63, TP63, p63 | |
| Molecular Weight | |
| 63kDa | |
| Chromosomal Location | |
| 3q28 | |
| Curated Database and Bioinformatic Data | |
| Gene Symbol | TP63 |
| Entrez Gene ID | 8626 |
| Ensemble Gene ID | ENSG00000073282 |
| RefSeq Protein Accession(s) | NP_003713, XP_016862876, NP_001108451, NP_001108454, XP_005247901, NP_001108450, NP_001316073, NP_001316074, NP_001316077, NP_001108452, XP_005247900, NP_001316075, NP_001316079, XP_011511553, XP_011511554, NP_001108453, NP_001316078, NP_001316893 |
| RefSeq mRNA Accession(s) | XM_005247844, NM_001114978, NM_001114980, NM_001329145, NM_001329146, XM_017007387, NM_001114979, XM_005247843, NM_001114982, NM_001329144, NM_001329964, XM_011513252, NM_001329149, XM_011513251, NM_003722, NM_001329148 NM_001114981, NM_001329150 |
| RefSeq Genomic Accession(s) | NC_000003, NG_007550, NC_018914, |
| UniProt ID(s) | B7Z8X6, A0A0S2Z4N5, A0A141PNN4, A0A141PNN3, Q9H3D4, C9D7D0, A0A0S2Z4N6 |
| UniGene ID(s) | B7Z8X6, A0A0S2Z4N5, A0A141PNN4, A0A141PNN3, Q9H3D4, C9D7D0, A0A0S2Z4N6 |
| HGNC ID(s) | 15979 |
| Cosmic ID(s) | TP63 |
| KEGG Gene ID(s) | hsa:8626 |
| PharmGKB ID(s) | PA162406776 |
| General Description of p63. | |
| p63 is a homolog of the tumor suppressor p53. It is identified in basal cells in the epithelial layers of a variety of tissues, including epidermis, cervix, urothelium, breast and prostate. p63 was detected in nuclei of the basal epithelium in normal prostate glands ;however, it was not expressed in malignant tumors of the prostate. As a result, p63 has been reported as a useful marker for differentiating benign from malignant lesions in the prostate, particularly when used in combination with markers of high molecular weight cytokeratins and the prostate-specific marker AMACR (P504S). p63 has also been shown to be a sensitive marker for lung squamous cell carcinomas (SqCC), with a sensitivity of ~90%. Specificity for lung SqCC, vs. lung adenocarcinoma (LADC), is approximately 80%. In breast tissue, p63 has been identified in myoepithelial cells of normal ducts. | |
There are no reviews yet.